手术治疗胶质母细胞瘤患者的脑积水:治还是不治?
该回顾性研究分析了2009年10月至2023年10月期间接受手术的781例胶质母细胞瘤患者,其中28例(3.6%)在治疗期间出现脑积水。15例(54%)接受治疗,13例(46%)未治疗。脑积水治疗后平均改良Rankin量表显著改善(从4±1降至3±1,P=0.005),88%的病例症状改善,3例(20%)出现并发症。治疗使生存期延长102天,但无统计学显著差异。
要点
- 胶质母细胞瘤患者脑积水治疗决策需个体化,功能状态良好者治疗可能延长生存。
- 脑积水治疗后平均改良Rankin量表显著改善,88%症状缓解,并发症风险可接受。
- 治疗使生存期延长102天,但无统计学显著差异。
核心结论
- 对功能状态良好的胶质母细胞瘤脑积水患者,治疗可缓解症状、改善功能结局并可能延长生存,且并发症风险可接受。
研究设计与样本
- 回顾性分析2009年10月至2023年10月单中心接受手术的781例胶质母细胞瘤患者,其中28例(3.6%)出现脑积水。
主要发现
- 28例脑积水患者中,13例(46%)未治疗,15例(54%)接受治疗。
- 治疗组中9例(60%)行脑室腹腔分流,3例(20%)行内镜手术,2例(13.3%)行外引流,1例(6.6%)行血肿清除。
- 治疗后平均改良Rankin量表从4±1改善至3±1(P=0.005),88%的病例症状改善。
- 3例(20%)出现手术并发症。
- 治疗使生存期延长102天(98天[四分位距,34;201] vs. 200天[四分位距,45;501]),但无统计学显著差异。
临床怎么用
- 对胶质母细胞瘤合并脑积水患者,应评估脑积水前的功能状态,功能良好者可考虑积极治疗脑积水以改善症状和功能。
局限性
- 回顾性单中心研究,样本量小(28例脑积水患者),生存获益未达统计学显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to overall poor prognosis in glioblastoma (GB) patients, the decision whether and how to treat hydrocephalus is challenging. The aim of this study is to analyze the indication and decision-making, as well as functional outcome and overall survival of GB patients treated for hydrocephalus. METHODS: We retrospectively analyzed patients who underwent surgery for GB between October 2009 and October 2023 at our department. The indication for treatment and treatment method were recorded. Further, patient and tumor characteristics, radiologic features, overall survival, as well as functional outcome based on the modified Rankin scale und Karnofsky index were assessed and compared between treated and the nontreated group. RESULTS: Out of the 781 GB patients, we identified 28 patients (3.6%) who developed hydrocephalus during treatment. Overall, 13 (46%) patients received no treatment, and 15 (54%) patients received treatment for hydrocephalus. Hereof, 9 (60%) patients were treated with ventriculoperitoneal shunt, 3 (20%) with endoscopic procedures, 2 (13.3%) with external ventricular drainage, and one (6.6%) with hematoma evacuation. Mean modified Rankin scale significantly improved after treatment of hydrocephalus (from 4 ± 1 to 3 ± 1, P = 0.005). In 88% of the cases, hydrocephalus treatment led to an improvement of the symptoms. In 3 patients (20%), complications occurred after surgical treatment of hydrocephalus. Hydrocephalus treatment prolonged survival by 102 days (98 days [interquartile range, 34; 201] vs. 200 days [interquartile range, 45; 501]) without statistically significant difference. CONCLUSIONS: The decision to treat hydrocephalus in GB patients depends on various factors and remains challenging. Treatment in patients with good functional status before hydrocephalus seems to prolong overall survival, leads to a relief in symptoms, and improves functional outcome with an acceptable risk of morbidity.
引用
- Westarp E, Leu S, Guzman R, et al. Hydrocephalus in Surgically Treated Glioblastoma Patients - To Treat or Not to Treat? World Neurosurg. 2025. PMID: 40516598. doi:10.1016/j.wneu.2025.124167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。